Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) announced its earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01), Zacks reports.
Spectral Diagnostics Trading Down 2.5%
Shares of EDTXF traded down $0.02 during mid-day trading on Friday, hitting $0.68. 3,000 shares of the company’s stock were exchanged, compared to its average volume of 9,166. Spectral Diagnostics has a fifty-two week low of $0.64 and a fifty-two week high of $1.10. The business’s 50 day moving average is $0.81 and its two-hundred day moving average is $0.94. The firm has a market capitalization of $201.15 million, a P/E ratio of -6.83 and a beta of 0.21.
About Spectral Diagnostics
Spectral Diagnostics Inc is a Canadian medical technology company focused on improving the diagnosis and treatment of sepsis and septic shock. The company develops products designed to identify endotoxin activity, an important factor in certain severe infections and inflammatory conditions.
Its principal diagnostic product is the Endotoxin Activity Assay, a blood test intended to measure a patient’s level of endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
See Also
- Five stocks we like better than Spectral Diagnostics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
